RedHill Biopharma Announced New Publication Of Data Showing That Triple Antimicrobial Therapy With RHB-104 Plus Standard Of Care, Targeting Mycobacterium Avium Subspecies Paratuberculosis, Is 64% More Effective Than SoC Alone In Crohn's Disease
RedHill Biopharma Announced New Publication Of Data Showing That Triple Antimicrobial Therapy With RHB-104 Plus Standard Of Care, Targeting Mycobacterium Avium Subspecies Paratuberculosis, Is 64% More Effective Than SoC Alone In Crohn's Disease
RedHill Biopharma宣佈的新數據出版物顯示，與標準治療相比，以RHb-104爲目標的三聯抗微生物治療對於克羅恩病更有效，提高百分之64。
RedHill Biopharma Announced New Publication Of Data Showing That Triple Antimicrobial Therapy With RHB-104 Plus Standard Of Care, Targeting Mycobacterium Avium Subspecies Paratuberculosis, Is 64% More Effective Than SoC Alone In Crohn's Disease
RedHill Biopharma宣佈的新數據出版物顯示，與標準治療相比，以RHb-104爲目標的三聯抗微生物治療對於克羅恩病更有效，提高百分之64。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。